{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:52:31Z","timestamp":1788778351803,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"MPIs","award":["R01CA214057"],"award-info":[{"award-number":["R01CA214057"]}]},{"name":"MPIs","award":["R01CA105274"],"award-info":[{"award-number":["R01CA105274"]}]},{"name":"MPIs","award":["U01CA195565"],"award-info":[{"award-number":["U01CA195565"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined risk of cardiovascular disease (CVD) events and mortality associated with endocrine therapy use in postmenopausal women with early-stage BC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Postmenopausal women diagnosed with stage I-III hormone receptor-positive BC from 2005 to 2013 were included (n\u2009=\u20098495). Women were classified as aromatase inhibitor (AI) users, tamoxifen users, and non-users of endocrine therapy in the 12\u2009months after BC diagnosis. Likelihood ratio tests examined whether the association of endocrine therapy use with CVD and mortality outcomes varied by body mass index (BMI) and history of CVD before BC diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over a median follow-up of 7.5\u2009years, women who used AIs were less likely to develop major adverse cardiovascular events (MACE) (HR\u2009=\u20090.84, 95% CI\u2009=\u20090.73 to 0.97) and heart failure (HR\u2009=\u20090.81, 95% CI\u2009=\u20090.66 to 0.99) compared with non-users of endocrine therapy. No associations between tamoxifen use and CVD outcomes were observed. AI use was associated with lower risk all-cause, CVD-related, and non-CVD-related mortality, compared with non-use of endocrine therapy. Tamoxifen use was associated with lower risk of all-cause mortality and non-CVD-related mortality, compared with non-use of endocrine therapy, and the association was modified by BMI (P for interaction &amp;lt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings suggest endocrine therapy use reduces all-cause mortality risk and may not increase CVD risk in postmenopausal women with early-stage hormone receptor-positive BC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djaf063","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:36:46Z","timestamp":1741779406000},"page":"1401-1409","source":"Crossref","is-referenced-by-count":8,"title":["Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-1627","authenticated-orcid":false,"given":"Yuhan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-3950","authenticated-orcid":false,"given":"Marilyn L","family":"Kwan","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7100-512X","authenticated-orcid":false,"given":"Susan R","family":"Heckbert","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-6971","authenticated-orcid":false,"given":"Cecile A","family":"Laurent","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janise M","family":"Roh","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-0437","authenticated-orcid":false,"given":"Eileen","family":"Rillamas-Sun","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie S","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5704-539X","authenticated-orcid":false,"given":"Tatjana","family":"Kolevska","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vallejo Medical Center , Vallejo, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5998","authenticated-orcid":false,"given":"Richard K","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-1839","authenticated-orcid":false,"given":"Carlos","family":"Irribarren","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-0282","authenticated-orcid":false,"given":"Mai","family":"Nguyen-Huynh","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]},{"name":"Kaiser Permanente Walnut Creek Medical Center , Walnut Creek, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-153X","authenticated-orcid":false,"given":"Dawn L","family":"Hershman","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-1175","authenticated-orcid":false,"given":"Lawrence H","family":"Kushi","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4148-1405","authenticated-orcid":false,"given":"Heather","family":"Greenlee","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]},{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]},{"name":"University of Washington School of Medicine , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2025070619563419900_djaf063-B1","volume-title":"SEER Cancer Statistics Review, 1975\u20132018","author":"Howlader","year":"2021"},{"key":"2025070619563419900_djaf063-B2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jnci\/djh253","article-title":"Probabilities of death from breast cancer and other causes among female breast cancer patients","volume":"96","author":"Schairer","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2025070619563419900_djaf063-B3","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"2025070619563419900_djaf063-B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnci\/djaa096","article-title":"All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort","volume":"113","author":"Ramin","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025070619563419900_djaf063-B5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025070619563419900_djaf063-B6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.21.01736","article-title":"Risk of cardiovascular disease in women with and without breast cancer: The Pathways Heart Study","volume":"40","author":"Greenlee","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025070619563419900_djaf063-B7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","journal-title":"Lancet"},{"key":"2025070619563419900_djaf063-B8","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3390\/cancers13092254","article-title":"Adjuvant hormonotherapy and cardiovascular risk in post-menopausal women with breast cancer: a large population-based cohort study","volume":"13","author":"Franchi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025070619563419900_djaf063-B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/heartjnl-2020-317510","article-title":"Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors","volume":"107","author":"Matthews","year":"2021","journal-title":"Heart"},{"key":"2025070619563419900_djaf063-B10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2021.07.004","article-title":"Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: a population-based cohort study","volume":"59","author":"Sund","year":"2021","journal-title":"Breast"},{"key":"2025070619563419900_djaf063-B11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"key":"2025070619563419900_djaf063-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.breast.2020.08.003","article-title":"Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: an analysis of nationwide data","volume":"54","author":"Choi","year":"2020","journal-title":"Breast"},{"key":"2025070619563419900_djaf063-B13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10549-018-05086-8","article-title":"Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors","volume":"174","author":"Xu","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2025070619563419900_djaf063-B14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/clc.23114","article-title":"Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study","volume":"42","author":"Kamaraju","year":"2019","journal-title":"Clin Cardiol"},{"key":"2025070619563419900_djaf063-B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2016.08.022","article-title":"The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer","volume":"68","author":"Abdel-Qadir","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025070619563419900_djaf063-B16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.21.01738","article-title":"Risk of cardiometabolic risk factors in women with and without a history of breast cancer: The Pathways Heart Study","volume":"40","author":"Kwan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025070619563419900_djaf063-B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"key":"2025070619563419900_djaf063-B18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2023"},{"key":"2025070619563419900_djaf063-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.021","article-title":"Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: a population-based study","volume":"301","author":"Casula","year":"2020","journal-title":"Atherosclerosis"},{"key":"2025070619563419900_djaf063-B20","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3390\/nu14122369","article-title":"Cardiovascular safety and effectiveness of bisphosphonates: from intervention trials to real-life data","volume":"14","author":"Delli Poggi","year":"2022","journal-title":"Nutrients"},{"key":"2025070619563419900_djaf063-B21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mayocp.2013.08.021","article-title":"Myocardial infarction risk among patients with fractures receiving bisphosphonates","volume":"89","author":"Pittman","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2025070619563419900_djaf063-B22","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1541-7786.MCR-17-0338","article-title":"Adipocytes sequester and metabolize the chemotherapeutic daunorubicin","volume":"15","author":"Sheng","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2025070619563419900_djaf063-B23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025070619563419900_djaf063-B24","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","article-title":"Cardiovascular disease after aromatase inhibitor use","volume":"2","author":"Haque","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025070619563419900_djaf063-B25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/07357907.2014.880452","article-title":"Association of aromatase inhibitors with coronary heart disease in women with early breast cancer","volume":"32","author":"Seruga","year":"2014","journal-title":"Cancer Invest"},{"key":"2025070619563419900_djaf063-B26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/aje\/kwaa065","article-title":"Cardiotoxicity of use of sequential aromatase inhibitors in women with breast cancer","volume":"189","author":"Khosrow-Khavar","year":"2020","journal-title":"Am J Epidemiol"},{"key":"2025070619563419900_djaf063-B27","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"2025070619563419900_djaf063-B28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"key":"2025070619563419900_djaf063-B29","doi-asserted-by":"crossref","first-page":"e026743","DOI":"10.1161\/JAHA.122.026743","article-title":"Effects of endocrine therapy on cardiovascular diseases and type 2 diabetes among breast cancer survivors: the National Health Insurance Service Database of Korea","volume":"11","author":"Kim","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025070619563419900_djaf063-B30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"2025070619563419900_djaf063-B31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025070619563419900_djaf063-B32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2025070619563419900_djaf063-B33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"2025070619563419900_djaf063-B34","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"2025070619563419900_djaf063-B35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","article-title":"Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27\u2014a randomized controlled phase III trial","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf063\/62385148\/djaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1401\/62385148\/djaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1401\/62385148\/djaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:56:46Z","timestamp":1751846206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/7\/1401\/8071569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf063","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,11]]}}}